Those who applied for < GV(045890) > hit the upper limit in just 1 day! Achieved 30% profit!
Congratulations to all 30 people who signed up for the free trial ^^ Thank you messages keep coming
The autoimmune treatment biosimilar Remsima (ingredient Infliximab) developed by ‘this company’ is currently undergoing clinical trials as a COVID-19 treatment and has shown excellent effects in treating COVID-19 patients. Separately, the COVID-19 antibody drug ‘CT-P59’ under development is in mild to moderate clinical trials. The upcoming emergency use approval news for CT-P59 is attracting investors’ attention.
“The free trial was a turning point for my stock trading. I was really curious how to make daily upper limit profits, but after seeing it in action, I was amazed. They provide stocks that hit the upper limit daily along with great information and education, so I am very satisfied. I am currently receiving VIP service and feel great to be able to do stocks for life. Thank you.”
(VIP full-time investor Choi Hyewon, 54 years old)
Now think of this as the last chance. If you miss this opportunity, you should quit.
Exactly “Exploding on November 04! Don’t miss it and regret it, buy at least 1 million KRW worth!
[AI recent upper limit hits]
*20.11.02 Syswork (269620) upper limit hit!
*20.10.30 Namseong (004270) upper limit hit!
*20.10.27 Phoenix Materials (050090) upper limit hit!
*20.10.23 ANP (015260) upper limit hit!
*20.10.21 Kyungin Electronics (009140) upper limit hit!
*20.10.19 KPX Life Science (114450) upper limit hit!
*20.10.16 Seohan (011370) upper limit hit!
*20.10.14 KMH Hightech (052900) upper limit hit!
*20.10.12 Access Bio (950130) upper limit hit!
*20.10.07 Camu ENC (013700) upper limit hit!
*20.10.05 Cellid (299660) upper limit hit!
▶▶ Exactly! Only for 10 people. “Wednesday Upper Limit”! ▶Get it now◀
※First-come, first-served 10 people only! Both early and late rounds are over. The hero of the last injury time winning goal※
[Today’s stocks of interest]
#Syswork #BoxelBio #ABProBio #W Holding Company #NextBT
※ This content is unrelated to the editorial direction of Asia Economy, and all responsibility lies with the information provider.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.

